|
1）石坂公成．我々の歩いて来た道―ある免疫学者の回想．MOKU出版．2000
|
|
|
|
|
2）日本アレルギー学会喘息ガイドライン専門部会，監修．喘息予防•管理ガイドライン 2015．東京：協和企画．2015
|
|
|
|
|
|
3）Global Initiative for Asthma （GINA）: Global strategy for asthma management and prevention. 2014 updated. http://www.ginasthma.org
|
|
|
|
|
|
4）Menz G, Ying S, Durham SR, et al. Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma. Allergy. 1998; 53: 15-21
|
|
|
|
|
5）Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 1996; 154: 1497-504
|
|
|
|
|
|
6）de Weck AL. Atopic and nonatopic IgE-mediated allergy: a new interpretation of old facts? Int Arch Allergy Immunol. 2002; 129: 97-107
|
|
|
|
|
|
7）Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43: 343-73
|
|
|
|
|
|
8）Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108: 184-90
|
|
|
|
|
|
9）Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab （anti-IgE） for asthma in inner-city children. N Engl J Med. 2011; 364: 1005-15
|
|
|
|
|
|
10）Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy （GINA 2002 step 4 treatment）: INNOVATE. Allergy. 2005; 60: 309-16
|
|
|
|
|
|
11）Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled （moderate-to-severe） allergic asthma. Allergy. 2004; 59: 701-8
|
|
|
|
|
|
12）Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170: 583-93
|
|
|
|
|
|
13）Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014; 13: 1
|
|
|
|
|
|
14）Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013; 187: 804-11
|
|
|
|
|
|
15）Arron JR, Choy DF, Scheerens H, et al. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc. 2013; 10 Suppl: S206-13
|
|
|
|
|
|
16）Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003; 21: 579-628
|
|
|
|
|
|
17）Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol. 2003; 3: 721-32
|
|
|
|
|
|
18）Bell EB, Jaffery G, Marshall JS. The physiological role of anti-IgE in rodents. Monogr Allergy. 1989; 26: 251-69
|
|
|
|
|
|
19）Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014; 14: 247-59
|
|
|
|
|
|
20）Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014; 2: 525-36
|
|
|
|
|
|
21）Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic （IgE-mediated） asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011; 72: 306-20
|
|
|
|
|
|
22）Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007; 39: 440-56
|
|
|
|
|
|
23）Bacharier LB, Geha RS. Molecular mechanisms of IgE regulation. J Allergy Clin Immunol. 2000; 105（2 Pt 2）: S547-58
|
|
|
|
|
|
24）Acharya M, Borland G, Edkins AL, et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol. 2010; 162: 12-23
|
|
|
|
|
|
25）Yodoi J, Hosoda M, Maeda Y, et al. Low affinity IgE receptors: regulation and functional roles in cell activation. Ciba Found Symp. 1989;147:133-48
|
|
|
|
|
|
26）Carlsson F, Hjelm F, Conrad DH, et al. IgE enhances specific antibody and T-cell responses in mice overexpressing CD23. Scand J Immunol. 2007; 66: 261-70
|
|
|
|
|
|
27）Lamers MC, Yu P. Regulation of IgE synthesis. Lessons from the study of IgE transgenic and CD23-deficient mice. Immunol Rev. 1995; 148: 71-95
|
|
|
|
|
|
28）Pène J. Regulatory role of cytokines and CD23 in the human IgE antibody synthesis. Int Arch Allergy Appl Immunol. 1989; 90 Suppl 1: 32-40
|
|
|
|
|
|
29）Poole JA, Meng J, Reff M, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005; 116: 780-8
|
|
|
|
|
|
30）Reichert JM. Technology evaluation: lumiliximab, Biogen Idec. Curr Opin Mol Ther. 2004; 6: 675-83
|
|
|
|
|
|
31）Poole JA, Meng J, Reff M, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005; 116: 780-8
|
|
|
|
|
|
32）Richards ML, Katz DH. Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine Fc epsilon RII （CD23）: comparison with the germline epsilon promoter. J Immunol. 1997; 158: 263-72
|
|
|
|
|
|
33）Rogala B, Rymarczyk B. Soluble CD23 in allergic diseases. Arch Immunol Ther Exp （Warsz）. 1999; 47: 251-5
|
|
|
|
|
|
34）Lorenzo GD, Mansueto P, Melluso M, et al. Serum levels of total IgE and soluble CD23 in bronchial asthma. Mediators Inflamm. 1996; 5: 43-6
|
|
|
|
|
|
35）Daher S, Santos LM, Solé D, et al. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J Investig Allergol Clin Immunol. 1995; 5: 251-4
|
|
|
|
|
|
36）Ohshima Y, Katamura K, Miura M, et al. Serum levels of interleukin 4 and soluble CD23 in children with allergic disorders. Eur J Pediatr. 1995; 154: 723-8
|
|
|
|
|
|
37）Marone G, Spadaro G, Palumbo C, et al. The anti-IgE/anti-FcepsilonRIalpha autoantibody network in allergic and autoimmune diseases. Clin Exp Allergy. 1999; 29: 17-27
|
|
|
|
|
|
38）Grattan CE, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991; 21: 695-704
|
|
|
|
|
|
39）Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993; 328: 1599-604
|
|
|
|
|
|
40）Chan YC, Ramadani F, Santos AF, et al. “Auto-anti-IgE”: naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation. J Allergy Clin Immunol. 2014; 134: 1394-401
|
|
|
|
|
|
41）Fick RB Jr, Jardieu PM. IgE and anti-IgE thepary in asthma and allergic disease （lung biology in health and disease）. CRC Press; 2002
|
|
|
|
|
|
42）Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012; 106: 1494-500
|
|
|
|
|
|
43）Steiss JO, Schmidt A, Rudloff S. Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay. Clin Lab. 2015; 61: 31-7
|
|
|
|
|
|
44）Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab （Xolair） therapy. J Immunol Methods. 2005; 303: 81-91
|
|
|
|
|
|
45）Steiß JO, Becher G. Optimisation of omalizumab dosage in patients with severe persistent allergic asthma using recovery ELISA. BioDrugs. 2014; 28: 445-50
|
|
|
|
|
|
46）Baker DL, Peng K, Cheu M, et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin. 2014; 30: 913-22
|
|
|
|
|
|
47）Ito R, Gon Y, Nunomura S, et al. Development of assay for determining free IgE levels in serum from patients treated with omalizumab. Allergol Int. 2014; 63 S1: 37-47
|
|
|
|